GlassScriptPhysician profile
Nadia Hammoud
NPI 1205368032
$117,344.03
in general payments reported to CMS, 2019-2025
30 companies · $28K in 2025
The $28K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35K · 2022: $52K · 2023: $715 · 2024: $1,522 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Consulting Fee: $7,013 · Food and Beverage: $4,212 · Travel and Lodging: $1,822 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,215.00 |
| Consulting Fee | $7,012.50 |
| Food and Beverage | $4,211.62 |
| Travel and Lodging | $1,822.01 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $45,298.32 | 2021-2025 | General - Dbs |
| Medtronic, INC. | $41,563.97 | 2021-2025 | Percept PC Brainsense, Activa PC |
| Neurocrine Biosciences, INC. | $27,055.00 | 2022-2025 | Ingrezza, Ongentys |
| Merz Pharmaceuticals, LLC | $771.11 | 2022-2025 | Xeomin, Inbrija |
| Abbvie INC. | $668.22 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $426.83 | 2021-2024 | Nuplazid |
| Inspire Medical Systems, INC. | $234.95 | 2024-2025 | Inspire |
| Insightec,INC | $168.95 | 2023-2024 | Exablate |
| Teva Pharmaceuticals USA, INC. | $164.17 | 2023-2025 | Ajovy, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $141.44 | 2024-2025 | |
| Abbott Laboratories | $122.60 | 2024 | Infinity |
| Kyowa Kirin, INC. | $102.63 | 2024 | Nourianz |
| Argenx US, INC. | $87.83 | 2022-2025 | Vyvgart Hytrulo |
| Lilly USA, LLC | $78.95 | 2024-2025 | Amyvid, Kisunla |
| Eisai INC. | $54.91 | 2023-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $46.79 | 2024-2025 | Horizant |
| Ge Healthcare | $42.26 | 2023 | |
| Aucta Pharmaceuticals, INC. | $35.83 | 2024-2025 | Motpoly Xr |
| Alexion Pharmaceuticals, INC. | $30.33 | 2023 | Ultomiris |
| Amneal Pharmaceuticals LLC | $28.82 | 2025 | Crexont |
| Ipsen Biopharmaceuticals, INC | $28.25 | 2025 | Dysport |
| Ucb, INC. | $27.73 | 2024 | Rystiggo |
| Takeda Pharmaceuticals U.S.A., INC. | $24.67 | 2024 | Hyqvia |
| Axsome Therapeutics, INC. | $24.06 | 2025 | Symbravo |
| Catalyst Pharmaceuticals, INC. | $22.62 | 2024 | |
| Supernus Pharmaceuticals, INC. | $22.49 | 2025 | Qelbree |
| Lundbeck LLC | $20.21 | 2025 | Vyepti |
| Biogen, INC. | $19.25 | 2024 | Vumerity, Tysabri |
| Grifols USA, LLC | $17.28 | 2025 | Gamunex-C |
| Livanova USA, INC. | $13.56 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Hammoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.